Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Healthy infants able to attend all study visits~* Parent(s)/legal representative able to read, understand, and complete study questionnaires~Exclusion Criteria~* History of congenital or acquired immunodeficiency~* Received or is expected to receive immunosuppressive agents or systemic immunomodulatory steroids~* History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disorder~* Hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines or concomitant study vaccines~* Has any chronic illness that could interfere with study conduct or completion~* Received any immune globulin, blood, or blood-derived products since birth~* Received a dose of hepatitis B vaccine prior to the study~* Vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, Haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, measles, mumps, rubella, or varicella vaccines, or any combination thereof~* Fever within 24 hours prior to enrollment~* Received any non-study vaccine within 30 days prior to enrollment, except for inactivated influenza vaccine, which is permitted 14 days or more prior to enrollment~* Has a coagulation disorder~* Has developmental delay or neurological disorder~* Participant or his/her mother has a medical history of hepatitis B surface antigen (HBsAg) seropositivity~* History of measles, mumps, rubella, varicella, Haemophilus influenzae type B, hepatitis B, diphtheria, tetanus, pertussis, rotavirus, invasive pneumococcal, or poliomyelitis infection

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 74 Days
- Healthy Volunteers: t

Study Arms:
- PR5I (Type: EXPERIMENTAL): V419 + RotaTeq + Prevenar 13 + ProQuad
- INFANRIX™ hexa (Type: ACTIVE_COMPARATOR): INFANRIX™ hexa + RotaTeq + Prevenar 13 + ProQuad

Based on this trial design, predict the completion outcome and termination type (if applicable).